Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
DAN-COVID: mRNA-1273 Vaccine Effectiveness in Adults Aged 50-64 Without Risk Factors
NCT07279766Phase 4Completed
- Start
- Dec 2025
- Primary completion
- Aug 2026
- Modality
- Vaccines & Immunotherapeutics, mRNA Therapeutics
- Countries
- 1
01
Overview
A Phase 4 trial of elasomeran in coronavirus disease 2019 (COVID-19). Started Dec 2025; status: completed.
02
Drugs
elasomeran
03
Conditions
coronavirus disease 2019 (COVID-19)
Beyond the preview
Go deeper on NCT07279766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07279766.